Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Theratechnologies (THTX)
:THTX
Holding THTX?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.05Last Year’s EPS
-0.08Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 21, 2019
|% Change Since: 41.80%
|Next Earnings Date:Oct 04, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive financial performance and growth for EGRIFTA SV, alongside challenges related to supply chain issues and declining sales for Trogarzo. Despite the supply disruptions, the company remains optimistic about its profitability and strategic direction.Company Guidance
During the Theratechnologies third quarter 2024 earnings call, significant guidance was provided, emphasizing both financial performance and strategic outlook. The company reported an adjusted EBITDA of $7.2 million and a net profit of $3 million for the quarter, with revenues increasing by 8% compared to the previous year, largely driven by EGRIFTA SV's double-digit growth. Due to a temporary manufacturing shutdown affecting EGRIFTA SV, Theratechnologies adjusted its revenue guidance for the full year to $83 million-$85 million. However, it increased its adjusted EBITDA guidance to $17 million-$19 million, highlighting a strategic focus on commercial activities and cost optimization. The company is confident in its ability to manage supply constraints, with sufficient inventory to meet patient demand until mid-January 2025, and anticipates making up for any shortfall in the first quarter of 2025. Theratechnologies also mentioned ongoing efforts to expand its product portfolio through potential in-licensing and partnerships, leveraging strong financial positioning to pursue new opportunities in the U.S. and Canadian markets.Profitability and Positive Financial Performance
Theratechnologies reported an adjusted EBITDA of $7.2 million and a net profit of $3 million for Q3 2024. Revenues increased by 8% compared to the same period last year, driven by the growth of EGRIFTA SV.
Strong EGRIFTA SV Performance
EGRIFTA SV recorded a 27% increase in sales year-over-year for Q3 2024, with double-digit growth in enrollments, unique patients, and units sold year-to-date.
Increased Adjusted EBITDA Guidance
Theratechnologies increased its adjusted EBITDA guidance for fiscal 2024 to $17 million to $19 million, reflecting strong operational performance.
Successful Cost Management
The company achieved significant cost reductions, with R&D expenses down 52% and G&A expenses down 19% year-over-year.
---
THTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
THTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 10, 2024 | $1.22 | $1.26 | +3.28% |
| Jul 10, 2024 | $1.55 | $1.50 | -3.23% |
| Apr 10, 2024 | $1.54 | $1.48 | -3.90% |
| Feb 21, 2024 | $1.68 | $1.70 | +1.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Theratechnologies (THTX) report earnings?
Theratechnologies (THTX) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Theratechnologies (THTX) earnings time?
Theratechnologies (THTX) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is THTX EPS forecast?
THTX EPS forecast for the fiscal quarter 2024 (Q4) is 0.05.
---